切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2021, Vol. 15 ›› Issue (06) : 609 -612. doi: 10.3877/cma.j.issn.1674-3946.2021.06.007

论著

DACT2基因启动子甲基化与乳腺浸润性导管癌细胞生物学特性的关系
王勇1,(), 李海军2   
  1. 1. 441400 湖北襄阳,宜城市人民医院普一科
    2. 830054 乌鲁木齐,新疆医科大学
  • 收稿日期:2020-07-06 出版日期:2021-12-26
  • 通信作者: 王勇

Relationship between promoter methylation of DACT2 gene and biological characteristics of breast invasive ductal carcinoma cells

Yong Wang1,(), Haijun Li2   

  1. 1. The first Department of general surgery, Yicheng people’s Hospital, Hubei Xiangyang 441400, China
    2. Xinjiang medical university, Wulumuqi 830054, China
  • Received:2020-07-06 Published:2021-12-26
  • Corresponding author: Yong Wang
  • Supported by:
    National Natural Science Foundation of China(81360328)
引用本文:

王勇, 李海军. DACT2基因启动子甲基化与乳腺浸润性导管癌细胞生物学特性的关系[J]. 中华普外科手术学杂志(电子版), 2021, 15(06): 609-612.

Yong Wang, Haijun Li. Relationship between promoter methylation of DACT2 gene and biological characteristics of breast invasive ductal carcinoma cells[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(06): 609-612.

目的

探究乳腺癌组织中DACT2基因启动子甲基化与乳腺浸润性导管癌细胞生物学特性的关系。

方法

2018年2月至2019年12月获取20例正常乳腺组织设为正常乳腺组(取自体检需要进行乳腺活检者)、60例乳腺癌旁组织设为乳腺癌旁组、60例乳腺癌组织设为乳腺癌组。应用RT-PCR技术检测三组DACT2 mRNA表达情况,DACT2甲基化技术检测DACT2甲基化状态,Transwell实验检测侵袭转移情况。采用SPSS20.0统计分析软件进行处理;计量资料采用(±s)表示,组间比较采用LSD-t检验;计数资料采用百分率(%)表示,组间比较采用χ2分析;P<0.05表示差异有统计学意义。

结果

乳腺癌组中DACT2基因甲基化阳性率较乳腺癌旁组和正常乳腺组高(P<0.05)。乳腺癌旁组与正常乳腺组组织中DACT2基因甲基化发生率差异无统计学意义(P>0.05)。在乳腺癌甲基化中DACT2基因mRNA相对表达量低于非甲基化组(P<0.05)。乳腺癌组织出现不同程度的胞膜表达缺失。体外侵袭转移试验检测乳腺癌组织细胞的侵袭转移能力发现,乳腺癌组织中DACT2基因启动子甲基化高的模型组的细胞迁移能力上调(P<0.05)。乳腺癌组织中DACT2基因启动子甲基化低的模型组的细胞凋亡上调(P<0.05)。

结论

抑制乳腺癌组织中DACT2基因启动子甲基化可降低乳腺浸润性导管癌细胞侵袭和转移,同时上调其凋亡。

Objective

To explore the relationship between promoter methylation of DACT2 gene in breast cancer and biological characteristics of invasive ductal carcinoma cells.

Methods

From February 2018 to December 2019, 20 normal breast tissues were selected as normal breast group (from those who need breast biopsy due to physical examination), 60 cases of breast cancer adjacent tissues were selected as breast cancer adjacent group, and 60 cases of breast cancer tissues were set as breast cancer group. DACT2 mRNA expression was detected by RT-PCR, DACT2 methylation was detected by DACT2 methylation, and invasion and metastasis were detected by Transwell assay. SpSS20.0 statistical analysis software was used for processing; measurement data was expressed by (±s), and LSD-t test was used for comparison between groups; count data was expressed by percentage (%), and χ2 analysis was used for comparison between groups; P<0.05 indicated statistically significant difference.

Results

The positive rate of DACT2 gene in breast cancer group was higher than that in breast cancer group and normal breast group (P<0.05). There was no significant difference in the incidence of DACT2 gene between breast cancer group and normal breast group (P>0.05). The relative expression of DACT2 gene mRNA in breast cancer group was lower than that in non methylation group (P<0.05). There are different degrees of cell membrane expression loss in breast cancer tissue. The invasion and metastasis ability of breast cancer tissue cells was detected by in vitro invasion and metastasis test. It was found that the cell migration ability of the model group with high methylation of DACT2 gene in breast cancer tissues was upregulated (P<0.05). The apoptotic cells in the model group with low methylation of DACT2 promoter in breast cancer tissues were up-regulated (P<0.05).

Conclusion

Inhibition of methylation of DACT2 promoter in breast cancer tissue can reduce invasion and metastasis of breast infiltrating ductal carcinoma cells and increase its apoptosis.

表1 60例乳腺癌患者临床一般病理特征
图1 DACT2 mRNA在乳腺癌组织、癌旁组织及正常乳腺中组织的表达
图2 乳腺癌组织中细胞侵袭能力测定
图3 乳腺癌组织细胞凋亡情况测定
表2 乳腺癌组织中DACT2基因启动子甲基化低的细胞转染组的细胞迁移能力(±s)
[1]
郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志201941(1):19-28.
[2]
杨红波,杜志权,马立岩,等. 动态增强MRI与乳腺DR钼靶对致密型乳腺T1及Tis期乳腺癌诊断的价值分析[J]. 中国CT和MRI杂志202119(1):101-103.
[3]
陈万青,孙可欣,郑荣寿. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤201827(1):1-14.
[4]
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice[J]. J Pathol2020250(5): 667-684.
[5]
Padmanabhan R, Kheraldine HS, Meskin N, et al. Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models[J]. Cancers (Basel)202012(3):636.
[6]
Romero Y, Wise R, Zolkiewska A. Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells[J]. Cancer Immunol Immunother202069(1):43-55.
[7]
Wu W-R, Sun H, Zhang R, et al. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targetingBMI1[J]. Oncotarget20167(14):18684-18693.
[8]
刘峥,杨基鹏,任思媛,等. 保留乳头的乳腺癌切除术在早期乳腺癌患者中临床效果研究[J/CD]. 中华普外科手术学杂志(电子版)202014(3): 273-276.
[9]
崔志超,马杰,王雅琪,等. HER2阳性乳腺癌患者新辅助化疗后免疫分型变化的研究[J/CD]. 中华普外科手术学杂志(电子版)202014(2): 189-192.
[10]
李传书,葛述科,高伟,等. 大连市不同型别乳腺癌患者的临床病理特征与生存状况研究[J/CD]. 中华普外科手术学杂志(电子版)202014(3): 268-272.
[11]
Guo L, Wang X, Yang Y, et al. Methylation of DACT2 contributes to the progression of breast cancer through activating WNT signaling pathway[J]. Oncol Lett201815(3):3287-3294.
[12]
Lasseigne BN, Brooks JD. The Role of DNA Methylation in Renal Cell Carcinoma[J]. Mol Diagn Ther201822(4):431-442.
[13]
Lin B, Hong HJ, Jiang XJ, et al. WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival[J]. Gene2017622:42-49.
[14]
Ray S, Khassawna TEI, Sommer U, et al. Differences in expression of Wnt antagonist Dkk1 in healthy versus pathological bone samples[J]. J Microsc2017265(1):111-120.
[15]
Borgonio-Cuadra VM, Miranda-Duarte A, Rojas-Toledo X, et al. Association between promoter hypermethylation of the DACT2 gene and tumor stages in breast cancer[J]. J BUON201823(2):361-365.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[11] 冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[12] 董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[13] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[14] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
[15] 屈洪波, 朱芳, 徐喆, 武楠, 何建怀, 王先明. 经肌间入路行锁骨下淋巴结清扫在局部晚期乳腺癌中的应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 510-513.
阅读次数
全文


摘要